Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 853891, 7 pages
http://dx.doi.org/10.1155/2015/853891
Research Article

Novel 3′-Processing Integrase Activity Assay by Real-Time PCR for Screening and Identification of HIV-1 Integrase Inhibitors

1Research Institute for Health Sciences, Chiang Mai University, Chiang Mai 50200, Thailand
2Division of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand
3Biomedical Technology Research Unit, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand

Received 18 February 2015; Revised 13 April 2015; Accepted 17 April 2015

Academic Editor: Olivier Delelis

Copyright © 2015 Supachai Sakkhachornphop et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Levy, HIV and the Pathogenesis of AIDS, ASM Press, 2007.
  2. McGraw-Hill, HIV Replication, The McGraw-Hill Companies, 2006.
  3. P. O. Brown, “Integration of retroviral DNA,” Current Topics in Microbiology and Immunology, vol. 157, pp. 19–48, 1990. View at Google Scholar
  4. K. E. Yoder and F. D. Bushman, “Repair of gaps in retroviral DNA integration intermediates,” Journal of Virology, vol. 74, no. 23, pp. 11191–11200, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Munir, S. Thierry, F. Subra, E. Deprez, and O. Delelis, “Quantitative analysis of the time-course of viral DNA forms during the HIV-1 life cycle,” Retrovirology, vol. 10, no. 1, article 87, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. “FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients,” AIDS Alert, vol. 24, no. 9, pp. 106–107, 2009.
  7. F. Raffi and M. A. Wainberg, “Multiple choices for HIV therapy with integrase strand transfer inhibitors,” Retrovirology, vol. 9, article 110, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Charpentier, M. Karmochkine, D. Laureillard et al., “Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy,” HIV Medicine, vol. 9, no. 9, pp. 765–770, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. O. Delelis, I. Malet, L. Na et al., “The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation,” Nucleic Acids Research, vol. 37, no. 4, pp. 1193–1201, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Sakkhachornphop, C. F. Barbas, R. Keawvichit, K. Wongworapat, and C. Tayapiwatana, “Zinc finger protein designed to target 2-long terminal repeat junctions interferes with human immunodeficiency virus integration,” Human Gene Therapy, vol. 23, no. 9, pp. 932–942, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. Z. Debyser, P. Cherepanov, W. Pluymers, and E. de Clercq, “Assays for the evaluation of HIV-1 integrase inhibitors,” Methods in Molecular Biology, vol. 160, pp. 139–155, 2001. View at Google Scholar · View at Scopus
  12. R. A. Katz and A. M. Skalka, “The retroviral enzymes,” Annual Review of Biochemistry, vol. 63, pp. 133–173, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Wang, H. Klock, H. Yin et al., “Homogeneous high-throughput screening assays for HIV-1 integrase 3′-processing and strand transfer activities,” Journal of Biomolecular Screening, vol. 10, no. 5, pp. 456–462, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. S. Han, W. L. Xiao, P. K. Quashie et al., “Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors,” Antiviral Research, vol. 98, no. 3, pp. 441–448, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. S. K. Nutan, M. Modi, C. S. Dezzutti et al., “Extracts from Acacia catechu suppress HIV-1 replication by inhibiting the activities of the viral protease and Tat,” Virology Journal, vol. 10, article 309, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Garrido, C. De Mendoza, and V. Soriano, “Resistance to integrase inhibitors,” Enfermedades Infecciosas y Microbiologia Clinica, vol. 26, supplement 12, pp. 40–46, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. I. Malet, O. Delelis, M.-A. Valantin et al., “Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 4, pp. 1351–1358, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. E. DeJesus, D. Berger, M. Markowitz et al., “Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients,” Journal of Acquired Immune Deficiency Syndromes, vol. 43, no. 1, pp. 1–5, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Sato, T. Motomura, H. Aramaki et al., “Novel HIV-1 integrase inhibitors derived from quinolone antibiotics,” Journal of Medicinal Chemistry, vol. 49, no. 5, pp. 1506–1508, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. C. Chang, T. T. Ching, and W. J. Syu, “Assaying the activity of HIV-1 integrase with DNA-coated plates,” Journal of Virological Methods, vol. 59, no. 1-2, pp. 135–140, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. Y.-S. Han, P. Quashie, T. Mesplede et al., “A high-throughput assay for HIV-1 integrase 3′-processing activity using time-resolved fluorescence,” Journal of Virological Methods, vol. 184, no. 1-2, pp. 34–40, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. D. J. Hazuda, P. Felock, M. Witmer et al., “Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells,” Science, vol. 287, no. 5453, pp. 646–650, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. V. R. de Soultrait, P.-Y. Lozach, R. Altmeyer, L. Tarrago-Litvak, S. Litvak, and M. L. Andréola, “DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents,” Journal of Molecular Biology, vol. 324, no. 2, pp. 195–203, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Mazumder, N. Neamati, J. O. Ojwang, S. Sunder, R. F. Rando, and Y. Pommier, “Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures,” Biochemistry, vol. 35, no. 43, pp. 13762–13771, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Suedee, S. Tewtrakul, and P. Panichayupakaranant, “Anti-HIV-1 integrase compound from Pometia pinnata leaves,” Pharmaceutical Biology, vol. 51, no. 10, pp. 1256–1261, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Suedee, S. Tewtrakul, and P. Panichayupakaranant, “Anti-HIV-1 integrase activity of Mimusops elengi leaf extracts,” Pharmaceutical Biology, vol. 52, no. 1, pp. 58–61, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Tewtrakul, N. Nakamura, M. Hattori, T. Fujiwara, and T. Supavita, “Flavanone and flavonol glycosides from the leaves of Thevetia peruviana and their HIV-1 reverse transcriptase and HIV-1 integrase inhibitory activities,” Chemical and Pharmaceutical Bulletin, vol. 50, no. 5, pp. 630–635, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Wares, T. Mesplède, P. K. Quashie, N. Osman, Y. Han, and M. A. Wainberg, “The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness,” Retrovirology, vol. 11, no. 1, article 7, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. T. M. Jenkins, A. Engelman, R. Ghirlando, and R. Craigie, “A soluble active mutant of HIV-1 integrase: involvement of both the core and caeboxyl-terminal domains in multimerization,” Journal of Biological Chemistry, vol. 271, no. 13, pp. 7712–7718, 1996. View at Publisher · View at Google Scholar · View at Scopus
  30. M. C. Revenant, “‘Sandwich’ enzyme immunoassay for serum ferritin with polypropylene test tubes as the solid phase,” Clinical Chemistry, vol. 29, no. 4, pp. 681–683, 1983. View at Google Scholar · View at Scopus